Ventures L.P. 5Am Sells 52,317 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 52,317 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $6.85, for a total value of $358,371.45. Following the completion of the sale, the insider owned 2,783,781 shares in the company, valued at $19,068,899.85. This trade represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA traded up $0.08 during midday trading on Monday, reaching $6.95. The stock had a trading volume of 411,770 shares, compared to its average volume of 464,800. The company’s 50 day moving average price is $6.86 and its 200 day moving average price is $9.68. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.45. The firm has a market cap of $270.63 million, a price-to-earnings ratio of -1.76 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Equities analysts forecast that Entrada Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TRDA. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Roth Capital set a $10.00 target price on shares of Entrada Therapeutics in a research note on Friday, May 8th. Finally, Guggenheim lowered their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.50.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. State of Wyoming bought a new position in shares of Entrada Therapeutics during the 2nd quarter worth $37,000. Russell Investments Group Ltd. raised its stake in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after acquiring an additional 3,707 shares during the period. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics in the 2nd quarter valued at about $68,000. Jain Global LLC purchased a new stake in Entrada Therapeutics during the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC purchased a new stake in Entrada Therapeutics during the second quarter valued at about $72,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.